Antikörper‐Wirkstoff‐Konjugate: ein neues Konzept in der Krebstherapie

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Angewandte Chemie

• Publication date

  2014-04-07

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1002/ANGE.201307628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.

  2013cited by this paper
• Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

  2013cited by this paper
• Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

  2013cited by this paper
• A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

  2013cited by this paper
• A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

  2013cited by this paper
• Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.

  2013cited by this paper
• Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

  2013cited by this paper
• SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

  2013cited by this paper
• The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

  2012cited by this paper
• Engineering folate-drug conjugates to target cancer: from chemistry to clinic.

  2012cited by this paper
• A traceless vascular-targeting antibody-drug conjugate for cancer therapy.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• A total synthesis trilogy: calicheamicin γ1(I), Taxol®, and brevetoxin A.

  2012cited by this paper
• Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

  2012cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.

  2012cited by this paper
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

  2012cited by this paper
• High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes

  2012cited by this paper
• Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

  2012cited by this paper
• Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery.

  2012cited by this paper
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012cited by this paper
• Site-specific modification of ED-B-targeting antibody using intein-fusion technology

  2011cited by this paper
• Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

  2011cited by this paper
• Abstract 3616: Highly potent antibody-amanitin conjugates cause tumor-selective apoptosis

  2011cited by this paper
• Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

  2011cited by this paper
• Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

  2011cited by this paper
• Brentuximab Vedotin (SGN-35)

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.

  2011cited by this paper
• Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.

  2011cited by this paper
• Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

  2011cited by this paper
• Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

  2011cited by this paper
• Analytical methods for physicochemical characterization of antibody drug conjugates

  2011cited by this paper
• Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

  2011cited by this paper
• Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

  2010cited by this paper
• Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

  2010cited by this paper
• Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

  2010cited by this paper
• Microtubule-binding agents: a dynamic field of cancer therapeutics

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

  2010cited by this paper
• Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

  2010cited by this paper
• Cancer esearch apeutics , Targets , and Chemical Biology 285 , a Novel C 2-Aryl-Substituted Pyrrolobenzodiazepine er Prodrug That Cross-links DNA and Exerts Highly R ent Antitumor Activity

  2010cited by this paper
• Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

  2009cited by this paper
• The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity

  2009cited by this paper
• CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

  2009cited by this paper
• Abstract B120: Designing potent antibody‐drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• How do anti-mitotic drugs kill cancer cells?

  2009cited by this paper
• Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents

  2009cited by this paper
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

  2008cited by this paper
• Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

  2008cited by this paper
• Anti-CD30 diabody-drug conjugates with potent antitumor activity

  2008cited by this paper
• Humanization of antibodies.

  2008cited by this paper
• Monoclonal antibodies in cancer therapy: 25 years of progress.

  2008cited by this paper
• A history of cancer chemotherapy.

  2008cited by this paper
• Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

  2008cited by this paper
• Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

  2007cited by this paper
• CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms

  2007cited by this paper
• Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

  2007cited by this paper
• Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

  2006cited by this paper
• A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization.

  2006cited by this paper
• Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

  2006cited by this paper
• Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.

  2006cited by this paper
• Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*

  2006cited by this paper
• Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

  2006cited by this paper
• Semisynthetic maytansine analogues for the targeted treatment of cancer.

  2006cited by this paper
• Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97

  2006cited by this paper
• A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

  2005cited by this paper
• An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.

  2005cited by this paper
• Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry.

  2005cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.

  2005cited by this paper
• SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

  2004cited by this paper
• Glutathione metabolism and its implications for health.

  2004cited by this paper
• Recent developments in the maytansinoid antitumor agents.

  2004cited by this paper
• SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.

  2003cited by this paper
• Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.

  2003cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Tubulin and microtubules as targets for anticancer drugs.

  2003cited by this paper
• A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.

  2003cited by this paper
• Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

  2002cited by this paper
• An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.

  2002cited by this paper
• A BRIEF HISTORY OF CANCER CHEMOTHERAPY

  2002cited by this paper
• Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma

  2002cited by this paper
• A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

  2002cited by this paper
• Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

  2001cited by this paper
• Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

  2001cited by this paper
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001cited by this paper
• Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

  2000cited by this paper
• Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

  2000cited by this paper
• Site-specific Conjugation on Serine → Cysteine Variant Monoclonal Antibodies*

  2000cited by this paper
• Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

  1999cited by this paper
• Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

  1999cited by this paper
• Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans

  1998cited by this paper
• Phase II study of adozelesin in untreated metastatic breast cancer

  1998cited by this paper
• IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

  1997cited by this paper
• CC-1065 and the Duocarmycins: Synthetic Studies.

  1997cited by this paper
• Differential distribution of free and bound glutathione and cyst(e)ine in human blood.

  1996cited by this paper
• Total Synthesis of (-)-Maytansinol.

  1996cited by this paper

• Stereoselective Synthesis of α ‐ʟ‐Rhamnopyranosides from ʟ‐Rhamnal Employing Ruthenium‐Catalysis

  2022cites this paper
• Linker Hydrophilicity Modulates the Anticancer Activity of RGD–Cryptophycin Conjugates

  2020cites this paper
• Synthesis and Biological Characterization of Monomeric and Tetrameric RGD‐Cryptophycin Conjugates

  2020cites this paper
• AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies.

  2019cites this paper
• Innovative linker strategies for tumor-targeted drug conjugates.

  2019cites this paper
• Bridge‐Clamp Bis(tetrazine)s with [N] 8 π‐Stacking Interactions and Azido‐ s ‐Aryl Tetrazines: Two Classes of Doubly Clickable Tetrazines

  2019cites this paper
• Arylierungschemie für die Biokonjugation

  2019cites this paper
• Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold

  2019cites this paper
• Recent Chemical Approaches for Site‐Specific Conjugation of Native Antibodies: Technologies toward Next‐Generation Antibody–Drug Conjugates

  2019cites this paper
• Arylation Chemistry for Bioconjugation.

  2019cites this paper
• Dissociative Bioorthogonal Reactions

  2019cites this paper
• Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery

  2019cites this paper
• Bridge Clamp Bis-Tetrazines Stacked by [N]8-π-Interactions and Azido-s-Aryl Tetrazines: New Classes of Doubly Clickable Tetrazines.

  2019cites this paper
• Development of α-Gal-Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies.

  2019cites this paper
• Heteromultifunctional Oxazolones as Versatile Linkers for Click Chemistry Reactions

  2019cites this paper
• Bioconjugation with Maleimides: A Useful Tool for Chemical Biology.

  2018cites this paper
• Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin‐Targeted Conjugate

  2018cites this paper
• Highly Selective Directed Iridium‐Catalyzed Hydrogen Isotope Exchange Reactions of Aliphatic Amides

  2018cites this paper
• Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and αV β3 -Integrin Ligands for Tumor Targeting

  2018cites this paper
• Synthetic Cancer‐Targeting Innate Immune Stimulators Give Insights into Avidity Effects

  2018cites this paper
• A Catch‐and‐Release Approach to Selective Modification of Accessible Tyrosine Residues

  2018cites this paper
• Entwicklung Pyrrolobenzodiazepin(PBD)‐haltiger Antikörper‐Wirkstoff‐Konjugate (ADCs) ausgehend von Anthramycin

  2017cites this paper
• Targeting Integrin αVβ3 with Theranostic RGD‐Camptothecin Conjugates Bearing a Disulfide Linker: Biological Evaluation Reveals a Complex Scenario

  2017cites this paper
• Dual, Site‐Specific Modification of Antibodies by Using Solid‐Phase Immobilized Microbial Transglutaminase

  2017cites this paper
• Nucleic Acid Templated Reactions for Chemical Biology

  2017cites this paper
• Synthesis and Cytotoxicity Evaluation of C4‐ and C5‐Modified Analogues of the α,β‐Unsaturated Lactone of Pironetin

  2017cites this paper
• Modular Assembly of Reversible Multivalent Cancer-Cell-Targeting Drug Conjugates.

  2017cites this paper
• Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents.

  2017cites this paper
• Modular Assembly of Reversible Multivalent Targeting Drug Conjugates

  2017cites this paper
• ortho‐Quinones and Analogues Thereof: Highly Reactive Intermediates for Fast and Selective Biofunctionalization

  2017cites this paper
• The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payloads with Antibody-Drug Conjugates.

  2016cites this paper
• From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)

  2016cites this paper
• Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates

  2016cites this paper
• Palladium-Catalyzed Chemoselective and Biocompatible Functionalization of Cysteine-Containing Molecules at Room Temperature.

  2016cites this paper
• Chemical Protein Modification through Cysteine

  2016cites this paper
• Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen.

  2016cites this paper
• Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

  2016cites this paper
• Synthetisch gewonnene Naturstofffragmente in der Wirkstoffentwicklung

  2016cites this paper
• Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages.

  2015cites this paper
• Site‐Specific Antibody Labeling by Covalent Photoconjugation of Z Domains Functionalized for Alkyne–Azide Cycloaddition Reactions

  2015cites this paper
• Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy.

  2015cites this paper
• Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

  2015cites this paper
• Targeted Delivery of Proteasome Inhibitors to Somatostatin‐Receptor‐Expressing Cancer Cells by Octreotide Conjugation

  2015cites this paper
• Advancing the drug discovery and development process.

  2014cites this paper
• Bio-reduction of redox-sensitive albumin conjugates in FcRn-expressing cells.

  2014cites this paper
• Cysteine-selective reactions for antibody conjugation.

  2014cites this paper
• Cysteinselektive Reaktionen zur Konjugation von Antikörpern

  2014cites this paper